Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03060720 · ClinicalTrials.gov registry record
Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy
A clinical trial of Pancreatic Cancer, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- 271
- Enrollment target
- 1
- Study location
NCT03060720 is a study of Pancreatic Cancer that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 271 participants, below the 392-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (31% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03060720, a study of Pancreatic Cancer, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- 271 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is looking at people with cancer of the pancreas to find clinical factors that can explain the presence of genetic mutations
Conditions Studied
Study Locations (1)
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 271 participants |
| Start Date | 2017-02-24 |
| Est. Completion | 2026-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03060720
The ClinicalTrials.gov registry entry for NCT03060720 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 271 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 392-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (31% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT03060720 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03060720 about?
NCT03060720 is a clinical study titled "Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy". This research study is looking at people with cancer of the pancreas to find clinical factors that can explain the presence of genetic mutations
What is the current status of trial NCT03060720?
This trial is currently active not recruiting. The enrollment target is 271 participants. The study started on 2017-02-24. Estimated completion is 2026-02.
What conditions does trial NCT03060720 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
Who is sponsoring clinical trial NCT03060720?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03060720 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.